©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Sugar Binding to Na/Glucose Cotransporters Is Determined by the Carboxyl-terminal Half of the Protein (*)

(Received for publication, December 22, 1995)

Mariana Panayotova-Heiermann (§) Donald D. F. Loo Cheng-Te Kong (1) Julia E. Lever (1) Ernest M. Wright

From the Department of Physiology, UCLA School of Medicine, Los Angeles, California 90095-1751 Department of Biochemistry and Molecular Biology, University of Texas Medical School, Houston, Texas 77225

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

D-Glucose is absorbed across the proximal tubule of the kidney by two Na/glucose cotransporters (SGLT1 and SGLT2). The low affinity SGLT2 is expressed in the S1 and S2 segments, has a Na:glucose coupling ratio of 1, a K(0.5) for sugar of 2 mM, and a K(0.5) for Na of 1 mM. The high affinity SGLT1, found in the S3 segment, has a coupling ratio of 2, and K(0.5) for sugar and Na of 0.2 and 5 mM, respectively. We have constructed a chimeric protein consisting of amino acids 1-380 of porcine SGLT2 and amino acids 381-662 of porcine SGLT1. The chimera was expressed in Xenopus oocytes, and steady-state kinetics were characterized by a two-electrode voltage-clamp. The K(0.5) for alpha-methyl-D-glucopyranoside (0.2 mM) was similar to that for SGLT1, and like SGLT1 the chimera transported D-galactose and 3-O-methylglucose. In contrast, SGLT2 transports poorly D-galactose and excludes 3-O-methylglucose. The apparent K(0.5) was 3.5 mM (at -150 mV), and the Hill coefficient ranged between 0.8 and 1.5. We conclude that recognition/transport of organic substrate is mediated by interactions distal to amino acid 380, while cation binding is determined by interactions arising from the amino- and carboxyl-terminal halves of the transporters. Surprisingly, the chimera transported alpha-phenyl derivatives of D-glucose as well as the inhibitors of sugar transport: phlorizin, deoxyphlorizin, and beta-D-glucopyranosylphenyl isothiocyanate are transported with high affinity (K(0.5) for phlorizin was 5 µM). Thus, the pocket for organic substrate binding is increased from 10 times 5 times 5 (Å) for SGLT1 to 11 times 18 times 5 (Å) for the chimera.


INTRODUCTION

Reabsorption of D-glucose from the glomerular filtrate along the proximal tubules of the kidney occurs by two apparently distinct cotransport systems(1, 2, 3) . In the S1 and S2 segments of the renal convoluted tubule, reabsorption is mediated to 90% by a low affinity Na/glucose cotransporter (SGLT2) (^1)with an apparent K(0.5) for sugar of 6 mM and a Na:glucose coupling ratio of 1. The reabsorption process is completed in the S3 segment by another Na/glucose cotransporter (SGLT1) with significantly higher apparent affinity for sugar (K(0.5) 0.35 mM) than SGLT2 and a Na/glucose coupling ratio of 2.

The pig renal cell line LLC-PK1 (4) has often been used as a model system to study glucose transport in kidney proximal epithelia. LLC-PK1 cells express Na/glucose transport activity (apparent K(0.5) 0.28 mM; (5) and (6) ) located at the apical surface(7) . The presence of SGLT1 (2:1 Na/glucose stoichiometry) in these cells was shown by Misfeldt and Sanders (8) and Moran et al.(9) . In 1990, Ohta et al.(10) isolated a SGLT1 cDNA clone (pSGLT1) from LLC-PK1 cells, with 84% and 87% identity to the high affinity rabbit and human SGLT1. There are three electrophysiologically characterized isoforms of the high affinity Na-dependent glucose transporter, the rat, human, and rabbit SGLT1s(11, 12, 13, 14, 15, 16) . All three isoforms show an apparent K(0.5) between 0.17 and 0.49 mM, an apparent K(0.5) of 2-7 mM, and a Hill coefficient >1.5.

Recently a low affinity Na/glucose cotransporter (pSGLT2) from LLC-PK1 cells was also cloned and functionally characterized(17, 18) . While the amino acid sequence of pSGLT2 was highly homologous to pSGLT1 (75% identical; 88% similar amino acid residues), the apparent K(0.5) for alphaMDG was 2 mM. Na/glucose stoichiometry for SGLT2 was 1, and the apparent K(0.5) 4-5 mM (at -150 mV). Phlorizin inhibited the alphaMDG-evoked currents with an apparent K of 18 µM, and D-galactose and 3-O-methylglucose were poor substrates for SGLT2.

Given the high similarity of the primary sequences and secondary structure of SGLT1 and SGLT2, what accounts for these differences in functional properties? Which parts of the proteins are involved in Na and sugar binding? To begin to answer these important questions, we generated a chimeric DNA-construct corresponding to amino acids 1-380, which form the putative transmembrane helices 1-8 of pSGLT2, and amino acids 381-662 (which form putative helices 9-14) of pSGLT1 (19) and compared its functionality with the parental proteins.


EXPERIMENTAL PROCEDURES

Molecular Biology Methods

A SpeI/StuI fragment from pig pSGLT2 in pBluescript SK (clone pCTK; (17) ) was ligated together with a StuI/XhoI fragment from porcine pSGLT1 (derived from clone pPSGT-B1; (10) ) and a SpeI/XhoI fragment from pMAMneo-SGLT1 plasmid (20) . The product of this three-fragment ligation was a chimeric sequence, coding for amino acids 1-380 from pig SGLT2 and amino acids 381-662 from pig SGLT1 (2.4-kilobase BamHI/XhoI coding fragment). To provide the chimeric DNA with the essential viral promoter sequence for in vitro transcription, and a poly(A) tail for expression in oocytes, the BamHI and XhoI 3`-ends were filled in by using Klenow enzyme. After purification by agarose gel electrophoresis, it was ligated into the SmaI site of the polylinker region of vector pAKS2(18) . This template DNA was linearized with EcoRI and transcribed in vitro and capped with SP6 RNA polymerase by using the Ambion MEGAscript transcription kit (Ambion, Austin, TX).

Oocyte Maintenance and Functional Assays

Mature Xenopus oocytes were manipulated as described previously (21) . Na-dependent alphaMDG or phlorizin influxes were measured by a standard procedure(22) , where groups of 7-10 control or cRNA-injected oocytes were incubated for 1 h in 5 µM [^3H]phlorizin (specific activity 47.6 Ci/mmol; DuPont NEN) or 50 µM [^14C]alphaMDG (specific activity 293 mCi/mmol; Amersham).

All two-microelectrode voltage clamp studies were controlled by the Clampex computer program of pCLAMP software (Axon Instruments, Foster City, CA) as described in (12) . During experiments measuring steady-state kinetics, the oocyte membrane voltage was first held at V(h) = -50 mV. Then step changes to 11 different test potentials (V(t)) in 20-mV intervals between +50 and -150 mV (each of a duration of 100 ms) were applied. The voltage pulse to the test potential was followed by return of the membrane voltage to the holding potential. Currents were averaged over three sweeps and low pass-filtered at 500 Hz by an eight-pole Bessel filter. Sugar-induced steady-state currents at different substrate concentrations [S] were fitted to by nonlinear regression analysis using Sigma Plot (Jandel, San Rafael, CA):

I represents the substrate (sugar or cation)-induced current, I(max) is the calculated maximal current, n is the coupling coefficient, and K(0.5) is the substrate concentration for 50% I(max).

Sugars and phenylglucosides were purchased from Sigma. Three-dimensional images of these were created by computational modeling based on the program Hyperchem 2.0 (Autodesk, Sausalito, CA) as described in (23) .

Multiple sequence alignments of the amino acid sequences were performed using the program PILEUP (Genetics Computer Group, Madison, WI).


RESULTS

Sugar- and Phlorizin-induced Steady-state Currents

Fig. 1A shows the current records for the chimera after the membrane voltage was stepped to various test values V(t) (+50, +30, -10, -110, and -150 mV) from the holding voltage V(h) (-50 mV). The left panel shows the currents in the absence of sugar in NaCl buffer, and the right panel the currents after 20 mM alphaMDG was added to the bath solution. The current relaxation consisted of an initial capacitive transient (time constant 0.5-1 ms), followed by a slower decay (time constant approx11 ms, at +50 mV) to the steady-state. This slow component, most pronounced at the depolarizing potentials (Fig. 1A, left panel), is the pre-steady-state current of the chimera.


Figure 1: Na inward currents generated by the chimeric protein. A, current records for the chimera obtained 5 days post-cRNA injection in 100 mM NaCl, in the absence (left panel) and presence (right panel) of 20 mM alphaMDG. The oocyte membrane potential V was held at -50 mV and stepped to various test potentials V between +50 and -150 mV. Shown are the traces for voltage jumps to +50, +30, -10, -110, and -150 mV. B, steady-state current-voltage (I-V) relationships. Currents mediated by the chimera at 100 ms after applying the voltage jump are presented as a function of the test potential in the presence of 100 mM choline chloride, 100 mM NaCl, or 100 mM NaCl + 20 mM alphaMDG (left panel). The right panel shows the net alphaMDG-induced Na currents, after subtraction of the steady-state currents recorded in 100 mM NaCl from these induced by the addition of sugar substrate. C, steady-state I-V relationship of the inward currents induced by 100 µM phlorizin. The protocol is as described in B. The left panel shows the I-V curves in 100 mM choline chloride, 100 mM NaCl, and after the addition of 100 µM phlorizin for the same oocyte as presented in B. The right panel shows the I-V curve of the current induced by phlorizin.



The sugar-induced current is the difference in the steady-state currents in the presence and absence of sugar. Addition of the saturating concentration of alphaMDG to the bath solution evoked an increase of the inward current of -187 nA at -150 mV and completely eliminated the pre-steady-state current (Fig. 1A, right panel). The right panel of Fig. 1B shows the alphaMDG-induced current, measured on another oocyte, as a function of voltage. The current increased as the membrane potential increased from -50 to -150 mV, but did not reach saturation at the most negative voltage applied. The steady-state current at -150 mV was -89 nA.

When the choline chloride solution was replaced by NaCl, the chimera generated an inward current in the absence of sugar (Fig. 1B). This sugar-independent current, or Na-leak, has also been observed for SGLT1 (24) and SGLT2 (18) . The sugar-independent Na current of the parent proteins can be estimated either as the difference in the currents when external Na is replaced by choline (Fig. 1B, left panel) or as the current blocked by phlorizin in the absence of sugar. Phlorizin has been shown to block the sugar-independent current in SGLT1 (24, 14) and SGLT2(18) . Surprisingly, when phlorizin was added to the 100 mM NaCl buffer in the absence of sugar (on the same oocyte presented in Fig. 1B), there was an increase in inward current instead of a block (Fig. 1C, left panel). The current-voltage relationship of the current induced by 100 µM phlorizin is shown in the right panel of Fig. 1C and was similar in amplitude (-108 nA at -150 mV) as well in its voltage dependence to the current induced by 20 mM alphaMDG (Fig. 1B, right panel).

For the chimera, the ratio between the sugar-independent current (estimated by choline substitution as described above) and the sugar (alphaMDG)-mediated current was considerably higher than observed for both SGLT1 and SGLT2. Both parental transporters show a sugar-independent current (the Na- leak current) that is 10% of the sugar-mediated current(15, 18) . In contrast, the Na-leak current mediated by the chimera was relatively higher, 44% of the maximal current induced by 20 mM alphaMDG. Similar values were obtained in four additional experiments.

To confirm that the phlorizin- or alphaMDG-induced currents were accompanied by uptake of phlorizin or alphaMDG into the oocytes, we measured the uptake of radiolabeled phlorizin or sugar in 100 mM NaCl or 100 mM choline chloride. Fig. 2shows that oocytes expressing the chimera transported eight times more [^14C]alphaMDG and [^3H]phlorizin in 100 mM NaCl than noninjected oocytes. No phlorizin transport could be measured in SGLT1-cRNA injected oocytes, and 100 mM choline chloride did not support any uptake of phlorizin into oocytes injected with chimeric cRNA (not shown).


Figure 2: Transport of radioactive tracer substrates. Uptakes of 50 µM [^14C]alphaMDG or 5 µM [^3H]phlorizin were performed in 100 mM NaCl 5-6 days post cRNA injection. Oocytes expressing the chimera in [^14C]alphaMDG transported: 58 ± 12 pmol/h/oocyte, whereas noninjected oocytes transported 8 ± 2 pmol/h/oocyte. Phlorizin transport could be measured only in oocytes injected with chimeric cRNA (13 ± 1 pmol/h/oocyte), but not SGLT1 cRNA (1.5 ± 0.5 pmol/h/oocyte) or noninjected oocytes (1.5 ± 0.4 pmol/h/oocyte). Shown is the mean of four independent experiments performed with noninjected oocytes or oocytes injected with chimeric cRNA. The error bars are S.E.



The current induced by alphaMDG was strongly dependent on membrane voltage and increased with more negative test voltages. Fig. 3A shows that the current-voltage relationship at 20 mM alphaMDG did not saturate in the voltage range from +50 to -150 mV and reached values in different oocytes between -80 and -300 nA (at -150 mV). To obtain the apparent affinity constant for alphaMDG (K(0.5)) in 100 mM NaCl, currents induced by different sugar concentrations were fitted for each test voltage to . The obtained K(0.5) of 0.25 mM was close to the value for the high affinity transporter SGLT1 and voltage independent (Fig. 3B). Dependent on the level of expression the maximal sugar-induced current I(max) was between 90 and 250 nA (at -150 mV).


Figure 3: Steady-state kinetics of the alphaMDG-induced currents. To obtain the maximal induced current (I(max)) and the K(0.5) for alphaMDG for the chimera, the sugar-induced steady-state current at various [alphaMDG] concentrations (in mM: 0.01, 0.02, 0.05, 0.20, 0.50, 1, 2, 5, and 20) were fitted to , while the external Na concentration was fixed at 100 mM. Data for the high (SGLT1) and low affinity (SGLT2) Na/glucose cotransporters were obtained from Refs. 21 and 18, respectively. A, comparison of the current-voltage (calculated I(max)/V) relationship of the alphaMDG-induced Na inward currents for the chimera, the high affinity and the low affinity Na/glucose cotransporters. To compare the three I/V curves, the data have been normalized to the currents at -150 mV. B, comparison of the apparent K(0.5) for alphaMDG between the chimera, the high affinity and the low affinity Na/glucose cotransporters.



To obtain the kinetic description of phlorizin transport in 100 mM Na, the phlorizin-induced currents were measured as a function of different external phlorizin concentrations (0-100 µM). Similar to the I/V curve of the current induced by sugar (alphaMDG), the I/V curve of the current induced by phlorizin did not saturate in the voltage range from +50 mV to -150 mV (Fig. 1C, right panel). I(max) reached between -100 and -300 nA (at -150 mV) and was comparable to the I(max). The apparent K(0.5) for phlorizin transport (K(0.5)) in 100 mM NaCl obtained from two experiments was 4.5 ± 0.8 µM and voltage independent (not shown).

Substrate Specificity

To determine the substrate specificity, we measured the steady-state currents induced by 20 mM concentrations of various substrates at -150 mV. For comparison between different substrates and among oocytes, the currents were normalized to the current mediated by 20 mMD-glucose, a saturating sugar concentration (Fig. 4). The substrates were divided into glucose analogues and phenylglucosides. The chimera showed highest affinity to D-glucose and alphaMDG and moderate affinity for D-galactose and 3-O-methylglucose. L-Glucose, 2-deoxyglucose, and mannose are nontransported sugars by either SGLT1 or SGLT2, and they also were not transported by the chimera. Phlorizin, the classical high affinity, nontransported competitive inhibitor of sugar transport (apparent K(i) between 1 and 10 µM; Refs. 16 and 25) evoked currents with even higher amplitude than D-glucose or alphaMDG. beta-D-Glucopyranosylphenyl isothiocyanate (GPITC), another inhibitor of SGLT1 (apparent K(i) of 100 µM; (23) ) was also transported. In contrast to SGLT1, the chimera recognized both enantiomers phenyl-alpha-D-glucopyranoside (alpha-PG) and phenyl-beta-D-glucopyranoside (beta-PG) with similar affinity, whereas beta-naphthyl glucoside, a substrate for SGLT1, was not transported. Only uridine and arbutin inhibited the Na-leak current by 13 ± 7% and 9.3 ± 5%, respectively.


Figure 4: Substrate specificity of the chimera. Each of the substrates was added to the bath solution for 2 min after the oocyte has been equilibrated in 100 mM NaCl. The exposure to different substrates was followed by washes in 100 mM choline chloride prior to re-equilibration in NaCl. The oocyte membrane potential was held at V = -50 mV. For comparison of data from different oocytes and substrates, we expressed the steady-state substrate-induced current (at -150 mV) as a ratio to the alphaMDG-induced current (at -150 mV), where the D-glucose-induced current was taken as 100%. All glucose analogues were tested at 20 mM and are indicated by the diagonal hatch. The applied concentrations of the different phenylglucosides were as follows: alpha- and beta-PG and arbutin, 10 mM; beta-Naph-Glc, 2.5 mM; Pz and deoxy-Pz, 0.1 mM; GPITC, 1 mM. 2-(Methylamino)isobutyrate (MeAIB) was tested at 2 mM, uridine at 20 mM, and their currents were indicated by the black bars.



Hager et al.(26) showed that for the high affinity rabbit SGLT1 the myo-inositol-induced current is about 10% of the alphaMDG-induced current and the apparent K(0.5) is 500 mM. The currents generated by the chimera in the presence of 20 mMmyo-inositol were higher than the myo-inositol-induced currents on SGLT1 and were 21 ± 7% of the control currents, suggesting a higher chimera affinity for myo-inositol.

Cation Effects Influencing the Transport by the Chimera

In addition to Na, Li and H supported sugar and phlorizin transport. Based on the current induced by 20 mM alphaMDG at -150 mV in the presence of 100 mM Na or Li, or at pH 5.5 (3.16 µM), the affinity of the chimera for the cations was in the order Na > Li approx H. The inward current induced by alphaMDG (20 mM) and phlorizin (100 µM) was similar for Na and Li. But in protons (pH 5.5), the phlorizin-induced current was higher than the current induced by alphaMDG. For example, in an experiment performed on the same oocyte, the phlorizin- and alphaMDG-induced inward currents at -150 mV were: -213 nA and -187 nA in Na, -67 nA and -52 nA in Li, and -80 nA and -48 nA in H. In 100 mM choline chloride at pH 7.5, phlorizin and alphaMDG did not induce any inward currents.

Fig. 5shows the dependence of the alphaMDG-induced Na-current on external Na concentration at -150 mV. The curve was drawn according to . The fit was poor as indicated by the large errors of the parameters, in part due to small inward currents at low external Na concentrations: I(max) = -76 ± 12 nA, K(0.5) = 3.4 ± 1.8 mM, and n = 0.8 ± 0.4. Similar results were obtained in 3 additional experiments. The apparent K(0.5) was independent of membrane voltage in the range -150 and -70 mV. The mean value of 3.3 ± 0.8 mM (n = 4, S.E.) at -150 mV, indicated a remained high affinity for Na at hyperpolarizing voltages. But in contrast to SGLT1 and SGLT2, the Hill coefficient for Na varied from 0.8 ± 0.4 (n = 4, S.E.) at -150 mV to 1.5 ± 0.6 (n = 4, S.E.) at -70 mV. For voltages more positive than -70 mV, we were unable to obtain estimates of K(0.5) and n for Na because of the large parameter errors.


Figure 5: Na activation of the steady-state current. The Na concentration of the bath solution [Na] was varied between 0 and 100 mM (0, 0.5, 1, 5, 10, 20, 50, 70, and 100), whereas [alphaMDG] was maintained at 20 mM. Shown is the dependence of the steady-state current at -150 mV with increasing [Na]. The curve is drawn according to the fit.




DISCUSSION

To date, little information is available on domains or residues responsible for ion and organic substrate recognition and binding in the family of Na/glucose cotransporters. In this study we show that functional chimeras can be obtained between homologous members of this family. We expressed a protein which according to the predicted topology for SGLT (19) consisted of putative membrane helices 1-8 of SGLT2 and putative membrane helices 9-14 of SGLT1.

K(0.5) and Substrate Specificity

The K(0.5) for the chimera of 0.2 mM and its voltage independence, as well as the specificity for the glucose analogues, D-galactose and 3-O-methylglucose, closely resembled those of the high affinity SGLT1 (see Fig. 3B and Fig. 4). In SGLT1, the affinity for D-galactose (K(0.5) 0.2 mM; (27) ) is similar to that for D-glucose, while the affinity for 3-O-methyl glucose is lower (K(0.5) 2-8 mM; (16) ). For SGLT2, D-galactose is a very poor substrate (it induces only 5% of the maximal glucose-induced current) with K(0.5) > 20 mM(18) and 3-O-methylglucose is not transported at all. The chimera transported D-galactose and 3-O-methylglucose with affinities which were similar to SGLT1 (the induced currents were >60% and 36% of the glucose-induced currents, respectively). Thus, the predominant phenotype of the chimera was clearly close to the high affinity transporters phenotype. Since the carboxyl-terminal half of the chimera was delivered by SGLT1, this indicates that the residues of the carboxyl-terminal half of the SGLT proteins determine the high affinity transport of sugar. This observation is similar to the galactose and glucose (Gal2) facilitated transporter from yeast, where the substrate recognition domain is in 101 amino acids close to the carboxyl terminus(28) . For the rat facilitated glucose transporter (GLUT1), the region encompassing membrane spans 7-12 was observed to have a crucial role in glucose transport(29) , and Due et al.(30) specified that the last 29 amino acids in the carboxyl-terminal tail are the important residues in determining the affinity to the substrate.

The phenylglucoside phlorizin is the most potent inhibitor of both SGLT1 and SGLT2, but it was transported by the chimera with high affinity. Dependent on the pH, the conformation of the aglucone of phlorizin (phloretin) varies between two tautomeric (keto-enol) forms. At pH 5.5, the absorption peak at 285 nm corresponds to the keto form, and, at pH 8.4, the maximal absorption at 320 nm is due to the enol form(31) . Between pH 5.5 and 8.5, we observed that maximal transport of phlorizin was at pH 5.5. This suggests that the chimera distinguishes between the two forms and transports the keto better than the enolic form. The keto form is always preferred whether it is in NaCl, choline chloride, or at various pH values. The most effective inhibition of sugar transport by phlorizin for SGLT1 is due also by the keto form. (^2)

In addition to phlorizin, other phenylglycosides which have been shown to be inhibitors of sugar transport in SGLT1 were transported by the chimera ( Fig. 4and Fig. 6A). Substituting the NCS group (in GPITC) for the OH group in para-position of the phenyl ring of arbutin converts this substrate for the high (23) and low affinity cotransporters into an inhibitor. (^3)GPITC inhibits the Na leak current of SGLT1, maybe by covalently binding to a lysine residue 0.8 nm away from the sugar binding pocket(32) . In contrast, this phenylglucoside is a good transport substrate for the chimera.


Figure 6: Superimposition of predicted three-dimensional structures of some phenylglucosides. The three-dimensional images of phenylglucosides were obtained by conformational search and energy minimizations as described in (23) . A, transported substrates by the chimera. Presented are the beta-phenylglucosides phlorizin, GPITC, and the alpha-phenylglucoside (alpha-PG). The phenyl ring of beta-phenylglucoside (beta-PG) superimposes with the phenyl ring of GPITC and is not explicitly indicated in the figure. B, transported substrates by the high-affinity SGLT1 isoforms. Arbutin is transported by all three SGLT1 isoforms from rat, rabbit, and human, whereas beta-Naph-Glc is transported by the rat and human isoforms, but not by rabbit SGLT1(16) .



alpha-Phenyl derivates of D-glucose are not transported by SGLT1(23) . Similar to GPITC, the chimera accepted the phenyl-alpha-D-glucopyranoside as well as the phenyl-beta-D-glucopyranoside (17% and 11% transport, respectively).

The superimposed three-dimensional geometry of the phenylglucoside substrates of the chimera (Fig. 6, upper panel) indicated outer dimensions of 11 times 18 times 5 (Å). The transport pocket for substrate in the case of the high affinity (SGLT1) human and rat isoforms is significantly smaller: 10 times 5 times 5 (Å), and the bulkiest known transported substrate is beta-Naph-Glc (Fig. 6B). The rabbit SGLT1 isoform does not transport this substrate(16) . Thus, we conclude that the chimera provides a less restrictive selectivity, compared to SGLT1 (comparable data are not yet available for SGLT2). In view of the transport of phlorizin, deoxyphlorizin, and GPITC by the chimera, its inability to transport beta-Naph-Glc is probably caused by the loss of specific interactions with the naphthyl moiety, rather than by a steric hindrance due to the bulky aglucone. In addition, since the chimera does not transport arbutin (see structural formulas in Fig. 6B), we speculate that in this case there is a lack of electrostatic interactions in the area surrounding the para-position of the phenyl ring.

Affinity for Cations by the Chimera

Since in both parental proteins, sugar transport is supported by Na, Li, and H(33, 34) and is similar to that observed in the chimera, no conclusions can be drawn on the location of the cation-recognizing domains by this construct. The parental proteins showed a major difference in their Hill coefficient for Na: n was 1 for SGLT2 and 2 for SGLT1(17) , and both were voltage independent. Because of the low amplitude of the sugar-evoked currents at low Na concentrations, the determination of the kinetic parameters K(0.5) and (especially) the Hill coefficient of the chimera became problematic. These parameters could not be estimated accurately and related to the low or high affinity transporters. Nevertheless, the chimera still possessed a high affinity for Na ions (3.5 mM at -150 mV). Analysis of new chimeras which combine the amino-terminal half of SGLT1 and the carboxyl-terminal half of SGLT2 could be successful in resolving the structural code for Na binding.

Comparison with Other Structure-Activity Studies on SGLT

The major conclusion of the present study is that the carboxyl termini of the SGLT family members modulate the selectivity and affinity for sugar substrates. This statement agrees with previous structure-function studies on site-directed mutants of SGLT1. Substitution of aspartic acid at position 176 (Asp-176) with alanine, influenced only the pre-steady-state kinetics and not the sugar-induced steady-state currents or the K(0.5)(21) . Replacement of a conservative lysine residue at position 321 (Lys-321) with alanine decreased dramatically the affinity for Na ions, while having secondary effects on sugar binding to the protein (35) . Both residues are in the amino-terminal half of SGLT1 and seem not substantially to effect sugar binding. In contrast, a missense mutation (R499H) from a patient with glucose/galactose malabsorption, localized close to the carboxyl terminus of the protein(36) , decreased the apparent affinity for sugar to human SGLT1 (K(0.5) raised to 2 mM), without affecting the apparent K(0.5).

Comparisons of the pre-steady-state (12) and the steady-state (16) kinetic parameters of the SGLT1s from rat, rabbit, and human have given initial ideas about residues that may account for the functional differences between these isoforms. Since the amino terminus (residues 1-27) and two hydrophilic loops located in the center (residues 229-271) and the carboxyl terminus (residues 548-644) involve most of the nonconserved polar residues between the three species, it has been proposed that they possibly contribute for charge movement and/or substrate specificity differences. The present study locates the sugar recognition domain distal to amino acid 380. Therefore, a comparison of the primary sequences distal to amino acids 380 of all cloned high affinity transporters from rat(11) , human(37) , rabbit(38) , and porcine(10) , with the corresponding sequence of the low affinity transporter from porcine(17, 18) , should specify individual amino acids that modulate sugar recognition (Fig. 7). According to the recently proposed topology for SGLT (19) and taking conservative substitution into account (K = R, S = T, D = E, Y = F = W, and I = V = L = M), our comparison localized differences in the loops between M10/M11, M12/M13, and M13/M14. In particular, in the loop M10/M11, two conserved serines (Ser-446, Ser-449) in the high affinity subfamily were substituted in SGLT2 by Val-446 and Asn-449; the conservative aspartic acid Asp-455 was substituted by a countercharge in SGLT2 (His-455), and, in the loop between M12/M13, two adjacent conservative residues Glu-514 and Pro-515 were both replaced in SGLT2 by a neutral alanine (Ala-514, Ala-515). The largest loop between M13/M14 contained most of the substitutions: a conservative serine (Ser-562) in the SGLT1s was replaced by an alanine (Ala-562) in SGLT2, and both conserved acidic residues (Glu-577) and aspartic acid (Asp-614) were missed in SGLT2. In the same loop, aspartic acid (Asp-580), isoleucine (Ile-581), and glutamine (Gln-582) were all replaced by positively charged residues in SGLT2: Lys-580, Arg-581, and His-582. A lysine (Lys-599) was converted into a threonine (Thr-599) in SGLT2, a methionine (Met-629) to a glutamine (Gln-629) and leucine (Leu-631) to an arginine (Arg-631). Any of these amino acids could contribute to the organic substrate binding. This easily could be tested by site-directed mutagenesis.


Figure 7: Amino acid sequence alignment of the SGLT family members. Shown are the sequences from the carboxyl-terminal halves of the high affinity cotransporters (SGLT1s) from porcine, human, rat, mouse, ovine, rabbit, and the low affinity cotransporter (SGLT2) from porcine. The dashes(- - -) represent identical residues and conservative substitutions (see text), and the shaded regions are putative membrane domains(19) . The residues in the SGLT1 family that are significantly different from residues in SGLT2 (dark regions) are depicted by bold letters.



The presented structure-functional analysis of a chimeric protein between two members of the SGLT family initiates a powerful strategy for further studies in localizing the structural determinants for cotransporter function.


FOOTNOTES

*
This research was supported by National Institutes of Health Grants DK4460 and DK 27400. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Dept. of Physiology, UCLA School of Medicine, 10833 Le Conte Ave., Los Angeles, CA 90095-1751. Tel.: 310-825-6905; Fax: 310-206-5661; mariana{at}physiology.medsch.ucla.edu.

(^1)
The abbreviations used are: SGLT1 (SGLT2), high (low) Na/glucose transporter for D-glucose; alphaMDG, alpha-methyl-beta-D-glucopyranoside; alpha-PG, phenyl-alpha-D-glucopyranoside; beta-PG, phenyl-beta-D-glucopyranoside; 3-O-Me-Glc, 3-O-methyl-beta-D-glucopyranoside; beta-Naph-Glc, beta-naphthyl beta-D-glucopyranoside; phloretin, (3[4-hydroxyphenyl]-1-[2,4,6-trihydroxyphenyl]-1-propanone; Pz, phlorizin, phloretin-2`-beta-D-glucoside; arbutin, 4-hydroxyphenyl beta-D-glucopyranoside; GPITC, beta-D-glucopyranosylphenyl isothiocyanate.

(^2)
B. A. Hirayama, personal communication.

(^3)
B. Mackenzie, manuscript in preparation.


ACKNOWLEDGEMENTS

We thank Dr. M. P. Lostao for advice in the preparation of the substrate overlays, Dr. E. Turk for help with the sequence alignments, and M. Contreras for excellent technical assistance.


REFERENCES

  1. Turner, R. J., and Moran, A. (1982) J. Membr. Biol. 67, 73-80 [Medline] [Order article via Infotrieve]
  2. Turner, R. J., and Moran, A. (1982) J. Membr. Biol. 70, 37-45 [Medline] [Order article via Infotrieve]
  3. Turner, R. J., and Moran, A. (1982) Am. J. Physiol. 242, F406-F414
  4. Hull, R. N., Cherry, W. R., and Weafer, G. W. (1976) In Vitro 12, 670-677 [Medline] [Order article via Infotrieve]
  5. Misfeldt, D. S., and Sanders, M. J. (1981) J. Membr. Biol. 59, 13-18 [Medline] [Order article via Infotrieve]
  6. Rabito, C. A., and Ausiello, D. A., (1980) J. Membr. Biol. 54, 31-38 [Medline] [Order article via Infotrieve]
  7. Rabito, C. A. (1981) Biochim. Biophys. Acta 649, 286-296 [Medline] [Order article via Infotrieve]
  8. Misfeldt, D. S., and Sanders, M. J. (1982) J. Membr. Biol. 70, 191-198 [Medline] [Order article via Infotrieve]
  9. Moran, A., Handler, J. S., and Turner, R. J. (1982) Am. J. Physiol. 243, C293-C298
  10. Ohta, T., Isselbacher, J. J., and Rhoads, D. B. (1990) Mol. Cell. Biol. 10, 6491-6499 [Medline] [Order article via Infotrieve]
  11. Lee, W.-S., Kanai, Y., Wells, R. G., and Hediger, M. A. (1994) J. Biol. Chem. 269, 12032-12039 [Abstract/Free Full Text]
  12. Panayotova-Heiermann, M., Loo, D. D. F., and Wright, E. M. (1995) J. Biol. Chem. 270, 27099-27105 [Abstract/Free Full Text]
  13. Loo, D. D. F., Hazama, A., Supplisson, S., Turk, E., and Wright, E. M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5767-5771 [Abstract]
  14. Parent, L., Supplisson, S., Loo, D. D. F., and Wright, E. M. (1992) J. Membr. Biol. 125, 49-62 [Medline] [Order article via Infotrieve]
  15. Parent, L., Supplisson, S., Loo, D. D. F., and Wright, E. M. (1992) J. Membr. Biol. 125, 63-79 [Medline] [Order article via Infotrieve]
  16. Hirayama, B. A., Lostao, M. P., Panayotova-Heiermann, M., Loo, D. D. F., Turk, E., and Wright, E. M. (1996) Am. J. Physiol. , in press
  17. Kong, C.-T., Yet, S.-F., and Lever, J. E. (1993) J. Biol. Chem. 268, 1509-1512 [Abstract/Free Full Text]
  18. Mackenzie, B., Panayotova-Heiermann, M., Loo, D. D. F., Lever, J. E., and Wright, E. M. (1994) J. Biol. Chem. 269, 22488-22291 [Abstract/Free Full Text]
  19. Turk, E., Kerner, C. J., Lostao, M. P., and Wright, E. M. (1996) J. Biol. Chem. 271, 1925-1934 [Abstract/Free Full Text]
  20. Kong, C.-T., Varde, A., and Lever, J. E. (1993) FEBS Lett. 333, 1-4 [CrossRef][Medline] [Order article via Infotrieve]
  21. Panayotova-Heiermann, M., Loo, D. D. F., Lostao, M. P., and Wright, E. M. (1994) J. Biol. Chem. 269, 21016-21020 [Abstract/Free Full Text]
  22. Ikeda, T. S., Hwang, E.-S., Coady, M. J., Hirayama, B. A., Hediger, M. A., and Wright, E. M. (1989) J. Membr. Biol. 110, 87-95 [Medline] [Order article via Infotrieve]
  23. Lostao, M. P., Hirayama, B. A., Loo, D. D. F., and Wright, E. M. (1994) J. Membr. Biol. 142, 161-170 [Medline] [Order article via Infotrieve]
  24. Umbach, J. A., Coady, M. J., and Wright, E. M. (1990) Biophys. J. 57, 1217-1224 [Abstract]
  25. Diedrich, D. (1990) Methods Enzymol. 191, 755-780 [Medline] [Order article via Infotrieve]
  26. Hager, K., Hazama, A., Kwon, H. M., Loo, D. D. F., Handler, J. S., and Wright, E. M. (1995) J. Membr. Biol. 143, 103-113 [Medline] [Order article via Infotrieve]
  27. Birnir, B., Loo, D. D. F., and Wright, E. M. (1991) Pflügers Arch. Eur. J. Physiol. 418, 79-85
  28. Nishizawa, K., Shimoda, E., and Kasahara, M. (1995) J. Biol. Chem. 270, 2423-2426 [Abstract/Free Full Text]
  29. Inukai, K., Katagiri, H., Takata, K., Asano, T., Anai, M., Ishihara, H., Nakazaki, M., Kikuchi, M., Yazaki, Y., and Oka, Y. (1995) Endocrinology 136, 4850-4857 [Abstract]
  30. Due, A. D., Zhi-Chao, Q., Thomas, J. M., Buchs, A., Powers, A. C., and May, J. M. (1995) Biochemistry 34, 5462-5471 [Medline] [Order article via Infotrieve]
  31. Fuhrmann, G. F., Dernedde, S., and Frenking, G. (1992) Biochim. Biophys. Acta 1110, 105-111 [Medline] [Order article via Infotrieve]
  32. Wright, E. M., Loo, D. D. F., Panayotova-Heiermann, M., Lostao, M. P., Hirayama, B., Mackenzie, B., Boorer, K., and Zampighi, G. (1994) J. Exp. Biol. 196, 197-212 [Abstract/Free Full Text]
  33. Hirayama, B. A., Loo, D. D. F., and Wright, E. M. (1995) Biophys. J. 68, A439
  34. Mackenzie, B., Loo, D. D. F., Panayotova-Heiermann, M., and Wright, E. M. (1994) Biophys. J. 68, A436
  35. Panayotova-Heiermann, M., Loo, D. D. F., and Wright, E. M. (1995) Pflügers Arch. Eur. J. Physiol. 430, (suppl.) R116
  36. Martín, M. G., Turk, E., Lostao, M. P., Kerner, C., and Wright, E. M. (1996) Nature Genet. 12, 216-220 [Medline] [Order article via Infotrieve]
  37. Hediger, M. A., Turk, E., and Wright, E. M. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 5748-5752 [Abstract]
  38. Hediger, M. A., Coady, M. J., Ikeda, T. S., and Wright, E. M. (1987) Nature 330, 379-381 [CrossRef][Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.